Pancreatic Cancer Research

ResearcherKansai Medical UniversityNo recent work listed

Satoshi Hirooka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1740-3645; OpenAlex author ID A5047013654. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 5 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers

Papers 24

  1. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Co-author DOI 10.1002/ags3.12608↗
  2. Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients. First author DOI 10.1080/01635581.2022.2107226↗
  3. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1026↗
  4. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  5. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therap… Co-author DOI 10.1007/s00595-021-02308-3↗
  6. Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKC… Co-author DOI 10.3892/ol.2021.12786↗
  7. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061428↗
  8. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Co-author DOI 10.1016/j.pan.2019.03.001↗
  9. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  10. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospectiv… Co-author DOI 10.1002/jhbp.447↗
  11. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Co-author DOI 10.1007/s00595-016-1358-9↗
  12. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  13. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal ade… Co-author DOI 10.1002/jhbp.408↗
  14. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  15. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarc… Co-author DOI 10.1080/01635581.2016.1134597↗
  16. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-016-0767-y↗
  17. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  18. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? Co-author DOI 10.1002/jhbp.119↗
  19. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000125↗
  20. Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. Co-author DOI 10.1007/s00534-012-0576-9↗
  21. Long-term results of surgical resection after preoperative chemoradiation in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318229758f↗
  22. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182373a66↗
  23. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderlin… Co-author DOI 10.1097/mpa.0b013e3182056b1c↗
  24. The role of circulating dendritic cells in patients with unresectable pancreatic cancer. Co-author PMID 22110205↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. So Yamaki · 24 shared papers, 2011–2023 · strength 1.89
  2. Tomohisa Yamamoto · 24 shared papers, 2011–2023 · strength 1.89
  3. Sohei Satoi · 23 shared papers, 2011–2023 · strength 1.65
  4. Hiroaki Yanagimoto · 20 shared papers, 2011–2023 · strength 1.29
  5. Mitsugu Sekimoto · 6 shared papers, 2020–2023 · strength 0.94
  6. Hironori Ryota · 9 shared papers, 2016–2021 · strength 0.71
  7. Daisuke Hashimoto · 4 shared papers, 2021–2023 · strength 0.60
  8. Tsukasa Ikeura · 3 shared papers, 2022–2023 · strength 0.47
  9. Masanori Kon · 7 shared papers, 2016–2017 · strength 0.39
  10. Yuki Matsui · 2 shared papers, 2022–2023 · strength 0.32
  11. Tatsuma Sakaguchi · 2 shared papers, 2021–2022 · strength 0.28
  12. A‐Hon Kwon · 8 shared papers, 2011–2015 · strength 0.27
  13. Satoshi Nishiwada · 4 shared papers, 2015–2019 · strength 0.23
  14. Naoya Ikeda · 4 shared papers, 2015–2019 · strength 0.23
  15. Masayuki Sho · 4 shared papers, 2015–2019 · strength 0.23
  16. Takahiro Akahori · 4 shared papers, 2015–2019 · strength 0.23
  17. Minako Nagai · 4 shared papers, 2015–2019 · strength 0.23
  18. Yuki Hashimoto · 2 shared papers, 2017–2019 · strength 0.15
  19. Yoshiyuki Nakajima · 3 shared papers, 2015–2016 · strength 0.14
  20. Shoichi Kinoshita · 3 shared papers, 2015–2016 · strength 0.14
  21. Koh Nakamaru · 1 shared paper, 2022 · strength 0.13
  22. Songtae Kim · 3 shared papers, 2012–2014 · strength 0.10
  23. Jun Yamao · 3 shared papers, 2012–2014 · strength 0.10
  24. Singh Sapam Opendro · 2 shared papers, 2014–2016 · strength 0.09
  25. Kota Nakamura · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.